<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00269204</url>
  </required_header>
  <id_info>
    <org_study_id>0524A-020</org_study_id>
    <secondary_id>MK0524A-020</secondary_id>
    <secondary_id>2005_095</secondary_id>
    <nct_id>NCT00269204</nct_id>
  </id_info>
  <brief_title>Lipid Efficacy/Tolerability Study (0524A-020)</brief_title>
  <official_title>A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A 28-week clinical trial in patients with primary hypercholesterolemia or mixed
      hyperlipidemia to study the effects of MK0524A on lipids and tolerability. There will be 9
      scheduled clinic visits, and 3 treatment groups. A patient can be randomly assigned to 1 of
      the 3 treatment groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reductions of LDL-C concentrations at 24 weeks and better tolerability</measure>
    <time_frame>at 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elevations in HDL-C concentrations at 24 weeks</measure>
    <time_frame>at 24 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1620</enrollment>
  <condition>Primary Hypercholesterolaemia</condition>
  <condition>Mixed Hyperlipidaemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>niacin (+) laropiprant</intervention_name>
    <description>Duration of Treatment - 24 weeks</description>
    <other_name>MK0524A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ER-niacin</intervention_name>
    <description>Duration of Treatment - 24 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 to 85 years of age with Primary Hypercholesterolemia or Mixed
             Hyperlipidemia with LDL-C below 100 mg/dL for high risk patients (patients with
             Coronary Artery Disease (CHD).

          -  Have medical conditions considered to be CHD equivalent).

          -  LDL-C below 130 mg/dL for patients with multiple risk factors.

          -  LDL-C between 130 and 190 mg/dL for patients with low risk and Triglycerides &lt;/= to
             350 mg/dL.

        Exclusion Criteria:

          -  A condition which, in the opinion of the investigator, might pose a risk to the
             patient or interfere with participating in the study, patients &lt; 20% compliance,
             patients with chronic medical conditions, patients with unstable doses of medications.

          -  Pregnant or lactating women, or women intending to become pregnant are excluded.

          -  Patient with diabetes mellitus that is poorly controlled, newly diagnosed, has
             recently experienced repeated hypoglycemia or unstable glycemic control, or is taking
             new or recently adjusted antidiabetic pharmacotherapy (with the exception of +/- 10
             units of insulin).

          -  Patients with the following conditions: chronic heart failure, uncontrolled/unstable
             cardiac arrhythmias, unstable hypertension, active or chronic hepatobiliary or hepatic
             disease, HIV positive, gout (within 1 year).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG; APPROVe Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006 Dec;131(6):1674-82. Epub 2006 Sep 1.</citation>
    <PMID>17087947</PMID>
  </reference>
  <reference>
    <citation>Maccubbin D, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, Sirah W, Betteridge A, Reyes R, Yu Q, Kuznetsova O, Sisk CM, Pasternak RC, Paolini JF. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008 Dec;62(12):1959-70. doi: 10.1111/j.1742-1241.2008.01938.x.</citation>
    <PMID>19166443</PMID>
  </reference>
  <reference>
    <citation>Bays HE, Maccubbin D, Meehan AG, Kuznetsova O, Mitchel YB, Paolini JF. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin Ther. 2009 Jan;31(1):115-22. doi: 10.1016/j.clinthera.2009.01.010.</citation>
    <PMID>19243712</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2005</study_first_submitted>
  <study_first_submitted_qc>December 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2005</study_first_posted>
  <last_update_submitted>July 24, 2015</last_update_submitted>
  <last_update_submitted_qc>July 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type V</mesh_term>
    <mesh_term>Lipidoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

